comparemela.com

Page 5 - Ableson Tyrosine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase.

United statesAlex loboMiltonh wernerCompany contactInhibikase or companyExchange commissionPrnewswire inhibikase therapeutics incSternir incNasdaq stock marketInhibikase therapeutics incAbelson tyrosine kinasesListing qualifications staffInhibikase therapeuticsNasdaq listing ruleAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

BOSTON and ATLANTA, July 17, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of.

United statesMiltonh wernerAlex loboPrnewswire inhibikase therapeutics incNasdaq stock marketInhibikase or companyCompany contactSternir incInhibikase therapeutics incExchange commissionAbelson tyrosine kinasesListing qualifications staffInhibikase therapeuticsNasdaq listing ruleAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase.

United statesAlex loboMiltonh wernerInhibikase or companyExchange commissionInhibikase therapeutics incCompany contactAmerican stock transfer trust companySternir incInhibikase therapeuticsAbelson tyrosine kinasesNasdaq capital marketAmerican stock transferTrust companyAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of

United statesMiltonh wernerAlex loboInhibikase or companyAmerican stock transfer trust companyCompany contactSternir incExchange commissionPrnewswire inhibikase therapeutics incInhibikase therapeutics incAbelson tyrosine kinasesNasdaq capital marketAmerican stock transferTrust companyAbelson tyrosine kinaseAbleson tyrosine

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the 501 Bioequivalence Study

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMilton wernerAlex loboMiltonh wernerExchange commissionSternir incInhibikase or companyInhibikase therapeutics incPrnewswire inhibikase therapeutics incCompany contactAbelson tyrosine kinasesChronic myelogenous leukemiaChief executive officerAbelson tyrosine kinaseOrphan drug designationAbleson tyrosine

vimarsana © 2020. All Rights Reserved.